Long-range effects in protein–ligand interactions mediate peptide specificity inl the human major histocompatibility antigen HLA-B27 (B*2701)
Stefan Krebs
Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC) and Universidad Autónoma de Madrid, Facultad de Ciencias, Cantoblanco, 28049 Madrid, Spain
Search for more papers by this authorDidier Rognan
Department of Pharmacy, ETH Zurich, Winterthurerstr. 190, 8057 Zurich, Switzerland
Search for more papers by this authorCorresponding Author
JOSÉ A.LÓPez De Castro
Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC) and Universidad Autónoma de Madrid, Facultad de Ciencias, Cantoblanco, 28049 Madrid, Spain
López de Castro, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Facultad de Ciencias, Cantoblanco, 28049 Madrid, SpainSearch for more papers by this authorStefan Krebs
Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC) and Universidad Autónoma de Madrid, Facultad de Ciencias, Cantoblanco, 28049 Madrid, Spain
Search for more papers by this authorDidier Rognan
Department of Pharmacy, ETH Zurich, Winterthurerstr. 190, 8057 Zurich, Switzerland
Search for more papers by this authorCorresponding Author
JOSÉ A.LÓPez De Castro
Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC) and Universidad Autónoma de Madrid, Facultad de Ciencias, Cantoblanco, 28049 Madrid, Spain
López de Castro, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Facultad de Ciencias, Cantoblanco, 28049 Madrid, SpainSearch for more papers by this authorAbstract
B*2701 differs from all other HLA-B27 subtypes of known peptide specificity in that, among its natural peptide ligands, arginine is not the only allowed residue at peptide position 2. Indeed, B*2701 is unique in binding many peptides with Gln2 in vivo. However, the mutation (Asp74Tyr) responsible for altered selectivity is far away from the B pocket of the peptide binding site to which Gln/Arg2 binds. Here, we present a model that explains this effect. It is proposed that a new rotameric state of the conserved Lys70 is responsible for the unique B*2701 binding motif. This side chain should be either kept away from pocket B through its interaction with Asp74 in most HLA-B27 subtypes, or switched to this pocket if residue 74 is Tyr as in B*2701. Involvement of Lys70 in pocket B would thus allow binding of peptides with Gln2. Binding of Arg2-containing peptides to B*2701 is also possible because Lys70 could adopt another conformation, H-bonded to Asn97, which preserves the same binding mode of Arg2 as in B*2705. This model was experimentally validated by mutating Lys70 into Ala in B*2701. Edman sequencing of the B*2701(K70A) peptide pool showed only Arg2, characteristic of HLA-B27-bound peptides, and no evidence for Gln2. This supports the computational model and demonstrates that allowance of B*2701 for peptides with Gln2 is due to the long-range effect of the polymorphic residue 74 of HLA-B27, by inducing a conformational switch of the conserved Lys70.
References
- Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF Ziegler A. 1978. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens—New tools for genetic analysis. Cell 14: 9–20.
-
Batalia MA,
Collins EJ.
1997.
Peptide binding by class I and class II MHC molecules.
Biopolymers
43:
281–302.
10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- Benjamin R, Parham P. 1990. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 11: 137–142.
- Benjamin RJ, Madrigal JA, Parham P. 1991. Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 351: 74–77.
- Boisgérault F, Tieng V, Stolzenberg MC, Dulphy N, Khalil I, Tamouza R, Charron D, Toubert A. 1996. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants: Implications for susceptibility to spondyloarthropathies. J Clin Invest 98: 2764–2770.
- Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. 1973. Ankylosing spondylitis and HLA 27. Lancet 1: 904–907.
- Calvo V, Rojo S, Lopez D, Galocha B, López de Castro JA. 1990. Structure and diversity of an HLA-B27-specific T-cell epitopes. Analysis with site-directed mutants mimicking HLA-B27 subtype polymorphism. J Immunol 144: 4038–4045.
- Clark M, Cramer RD III, van Opdenbosch N. 1989. Validation of the general purpose TRIPOS 5.2 force-field. J Comput Chem 10: 982–1012.
- Colbert RA, Rowland-Jones SL, McMichael AJ, Frelinger JA. 1994. Differences in peptide presentation between B27 subtypes: The importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. Immunity 1: 121–130.
- D'Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zuccarelli A, Bitti PP, Tosi R, Sorrentino R. 1995. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 25: 3199–3201.
- Ellis SA, Taylor C, McMichael AM. 1982. Recognition of HLA-B27 and related antigens by a monoclonal antibody. Hum Immunol 5: 49–56.
- Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290–296.
- Fiorillo MT, Meadows L, D'Amato M, Shabanowitz J, Hunt DF, Appella E, Sorrentino R. 1997. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 27: 368–373.
- Galocha B, Lamas JR, Villadangos JA, Albar JP, López de Castro JA. 1996. Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Tissue Antigens 48: 509–518.
- García F, Galocha B, Villadangos JA, Lamas JR, Albar JP, Marina A, López de Castro JA. 1997a. HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket. Tissue Antigens 49: 580–587.
- García F, Marina A, López de Castro JA. 1997b. Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated with ankylosing spondylitis. Tissue Antigens 49: 215–221.
- García F, Rognan D, Lamas JR, Marina A, López de Castro JA. 1998. An HLA-B27 polymorphism (B*2710) that is critical for T-cell recognition has limited effects on peptide specificity. Tissue Antigens 51: 1–9.
- Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. 1989. Specificity pockets for the side-chains of peptide antigens in HLA-Aw68. Nature 342: 692–696.
- Gonzalez-Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG, Housan L, Konenkov V, Abbadi MC, Grunnet N, Coto E, López-Larrea C. 1997. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 49: 116–123
- Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. 1990. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: An animal model of HLA-B27-associated human disorders. Cell 63: 1099–1112.
- Hermann E, Yu DT, Meyer zum Büschenfelde KH, Fleischer B. 1993. HLA-B27-restricted CD8 T-cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylits. Lancet 342: 646–650.
- Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. 1991. Identification of self peptides bound to purified HLA-B27. Nature 353: 326–329.
- Kingsley G, Sieper J. 1993. Current perspectives in reactive arthritis. Immunol Today 14: 387–391.
- Kraulis PJ. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24: 946–950.
- Krebs S, Lamas JR, Poenaru S, Folkers G, López de Castro JA, Seebach D, Rognan D. 1998. Substituting nonpeptidic spacers for the T-cell receptor-binding part of class I major histocompatibility complex-binding peptides. J Biol Chem 273: 19072–19079.
- Kunkel TA. 1985. Rapid and efficient site-specific mutagenesis without pheno-typic selection. Proc Natl Acad Sci USA 82: 488–492.
- López de Castro JA. 1998. The pathogenic role of HLA-B27 in chronic arthritis. Curr Opin Immunol 10: 59–66.
- López-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, Dominguez O, Coto E, Pena M, Setién F. 1995. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens 45: 169–176
- Madden DR. 1995. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 13: 587–682.
- Madden DR, Gorga JC, Strominger JL, Wiley DC. 1992. The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC. Cell 70: 1035–1048.
- Merritt EA, Murphy MEP. 1994. Raster3D version 2.0. A program for photorealistic molecular graphics. Acta Cryst D50: 869–873.
- Nasution AR, Mardjuadi A, Kunmartini S, Suryadhana NG, Setyohadi B, Sudarsono D, Lardy NM, Feltkamp TE. 1997. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 24: 1111–1114.
- Parker KC, Biddison WE, Coligan JE. 1994. Pocket mutations of HLA-B27 show that anchor residues act cumulatively to stabilize peptide binding. Biochemistry 33: 7736–7743.
- Raghavan M, Lebrón JA, Johnson JL, Bjorkman P. 1996. Extended repertoire of permissible ligands for HLA-B*2702. Protein Sci 5: 2080–2088.
- Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH. 1997. Possible protective role of HLA-B*2706 for ankylosing spondylitis. Tissue Antigens 49: 67–69
- Rognan D. 1998. Molecular modeling of protein-peptide complexes—Application to major histocompatibility proteins. Habilitationsschrift, Eidgenossiche Technische Hochschule (ETH), Zürich.
- Rognan D, Krebs S, Kuonen O, Lamas JR, López de Castro JA, Folkers G. 1997. Fine specificity of antigen binding to two class I major histocompatibility proteins (B*2705 and B*2703) differing in a single amino acid residue. J Comput-Aided Mol Design 11: 463–478.
- Rojo S, García F, Villadangos JA, López de Castro JA. 1993. Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B. J Exp Med 177: 613–620.
- Rötzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG. 1994. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 39: 74–77.
- Rovero P, Riganelli D, Fruci D, Vigano S, Pegoraro S, Revoltella R, Greco G, Butler R, Clementi S, Tanigaki N. 1994. The importance of secondary anchor residue motifs of HLA class I proteins: A chemometric approach. Mol Immunol 31: 549–554.
- Saper MA, Bjorkman PJ, Wiley DC. 1991. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J Mol Biol 219: 277–319.
- Simmons WA, Summerfield SG, Roopenian DC, Slaughter CA, Zuberi AR, Gaskell SJ, Bordoli RS, Hoyes J, Moomaw CR, Colbert RA. 1997. Novel HY peptide antigens presented by HLA-B27. J Immunol 159: 2750–2759.
- Smith KJ, Reid SW, Harlos K, McMichael AJ, Stuart DI, Bell JI, Jones EY. 1996a. Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC Class I HLA-B53. Immunity 4: 215–228.
- Smith KJ, Reid SW, Stuart DI, McMichael AJ, Jones EY, Bell JI. 1996b. An altered position of the α2 helix of MHC Class I is revealed by the crystal structure of HLA-B*3501. Immunity 4: 203–213.
- Tieng V, Dulphy N, Boisgérault F, Tamouza R, Charron D, Toubert A. 1997. HLA-B*2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes. Immunogenetics 47: 103–105.
- Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J. 1997. A single nonamer from the Yersinia 60 kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. J Immunol 159: 5715–5723.
- Villadangos JA, Galocha B, García F, Albar JP, López de Castro JA. 1995. Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703. Eur J Immunol 25: 2370–2377.
- Zhou M, Sayad A, Simmons WA, Jones RC, Maika SD, Satumtira N, Dorris ML, Gaskell SJ, Bordoli RS, Sartor RB, et al. 1998. The specificity of peptides bound to human histocompatibility leukocyte antigen HLA-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J Exp Med 188: 877–886.